Faculty

The University of Oklahoma Health Sciences Center
Stephenson Cancer Center
975 NE 10th St, BRC 417B
Oklahoma City, OK 73104

---

Education:

• MS - Biochemistry, University of Calcutta, India (1987)
• PhD - Biochemistry, University of Calcutta, India (1998)

---

Fellowship:

• Research Fellow -  Department of Microbiology, Bose Institute, Calcutta, India (1989-1997)
• Post-Doctoral Fellow - Department of Pathology, St. Louis University, St. Louis, MO (1998-1999)
• Research Associate - Department of Pathology, St. Louis University, St. Louis, MO (1999-2001)
• Research Associate - Division of Hematology, Mayo Clinic, Rochester, MN (2006-2008)

---

Memberships:

• American Society of Hematology  
• American Association for Cancer Research
• Member of the ASH Scientific Committee on Lymphoid Neoplasia, 2013 – present

---

Clinical/Research Interests:

• Chronic Lymphocytic Leukemia (CLL) cell biology
• Tyrosine Kinase (RTK & non-RTK) signaling
• Cell Survival Signaling Pathways
• Drug Targeting
• Small Molecule Inhibitors
• B Cell Lymphomas
• Tumor Microenvironment/Extracellular
• Vesicles

---

Funding:

R21CA274072      Asish Ghosh (PI)        7/7/2022 – 6/30/2025 (NCE)
NIH/NCI
Study Pro-oncogenic Role of BCL6 in CLL Tumorigenesis.
The proposed studies have potential to establish a new prognostic parameter and therapeutic avenue via targeting BCL6 in CLL cells in combination with the current BCR-targeted therapy, ibrutinib. Tumorigenesis.
Role: PI

R21CA274072      Asish Ghosh (PI)         4/10/2023 – 3/31/2025
NIH/NCI
Pro-Oncogenic Role of Mitochondrial Lipid Kinase in CLL.
The proposed studies have enormous potential to establish a new prognostic parameter and therapeutic avenue via targeting AGK in CLL cells with or without the current BCR-targeted therapy, ibrutinib.
Role: PI

---

Select Honors & Accomplishments:

• Fellowships from the Council of Scientific and Industrial Research (CSIR), Government of India
• Young Investigator Award, Mayo Clinic Angiogenesis Symposium (2008)
• Hematology Research Summit Award Recipient, Mayo Clinic (2012)

---

Select Publications:

1. Mamidi MK, et al. Idelalisib activates AKT via increased recruitment of PI3Kdelta/PI3Kbeta to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. 2022. Epub 20220514. doi: 10.1038/s41375-022-01595-0. PubMed PMID: 35568768.
2. Maiti GP, et al. SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. Blood Cancer J. 2021;11(5):93. Epub 2021/05/19. doi: 10.1038/s41408-021-00484-6. PubMed PMID: 34001853; PMCID: PMC8129117.
3. Sinha S, et al. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(9):2115-26. Epub 2015/02/13. doi: 10.1158/1078-0432.CCR-14-1892. PubMed PMID: 25673699.